Clinical trials
Inflammatory Breast Cancer clinical trials
Below are recruiting inflammatory breast cancer clinical trials, each written for real people, not researchers. We’re tracking 324 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07264985Recruiting
Gut bacteria and diarrhea in breast cancer patients on pyrotinib
This study looks at how gut bacteria relate to diarrhea in breast cancer patients who are taking a drug called pyrotinib. By understanding this link, doctors hope to better manage side effects in the future.
Wuhan, HubeiAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06162559RecruitingPhase 1
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
AmsterdamAges 18 years+ - NCT07658170Recruiting
Fat graft with platelet-rich fibrin for breast reconstruction after lumpectomy
This trial tests using a patient's own fat plus a special blood product (platelet-rich fibrin) to rebuild the breast right after a lumpectomy for breast cancer. It may help improve healing and appearance for women with early-stage, hormone-sensitive breast cancer.
Saint PetersburgAges 18–69 - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT04315233RecruitingPhase 1
Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Salt Lake City, UtahAges 18 years+ - NCT05992870Recruiting
Radiation before breast reconstruction with implants
This trial tests giving radiation therapy before surgery and immediate breast reconstruction using implants. It may help patients who need a mastectomy and know they will need radiation after.
Wuhan, HubeiAges 18–75 - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07043725RecruitingPhase 3
Neoadjuvant TQB2102 for HER2-positive breast cancer
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Bengbu, AnhuiAges 18–75 - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06891833RecruitingPhase 2/Phase 3
New drug combo for HER2-positive breast cancer before surgery
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Bengbu, AnhuiAges 18–75 - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06340230RecruitingPhase 2
New drug combination before surgery for HR+ HER2-low breast cancer
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
Shenyang, LiaoningAges 18–75 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT05883852RecruitingPhase 3
HER2-positive breast cancer trial for women with lymph node spread
This Phase 3 trial compares two post-surgery drug plans for HER2-positive early breast cancer that has spread to nearby lymph nodes. It may help reduce cancer recurrence by testing which regimen works better after surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Inflammatory Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inflammatory breast cancer?
- Yes. Clin2 currently lists 324 recruiting inflammatory breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inflammatory breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inflammatory breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.